Discovering Innovative Solutions

for Cystic Fibrosis

Explore our efforts

Nivalis Therapeutics, Inc.

Nivalis Therapeutics, is a clinical stage pharmaceutical company that focuses on the discovery, development, and commercialization of drug candidates for people with cystic fibrosis (CF). CF is a life-shortening genetic disease. Our lead candidate is cavosonstat, a pill that is in two Phase II clinical trials intended to address a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The Company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.

About Us

Leading Innovation in
Cystic Fibrosis

Innovative Engineering in Cystic Fibrosis.

Learn more  

Contact Nivalis

Nivalis Therapeutics, Inc.
3122 Sterling Circle
Boulder, CO 80301
720-945-7700

Contact Us  

Latest News

  • 7
    Oct.
  • Tue, 06 Sep 16 07:30:00 -0400

    Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

  • Download
  • 7
    Oct.
  • Mon, 01 Aug 16 16:05:00 -0400

    Nivalis Therapeutics Reports Second Quarter 2016 Financial Results

  • Download
  • 7
    Oct.
  • Thu, 07 Jul 16 07:00:00 -0400

    Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Wed, 06 Jul 16 16:05:00 -0400

    Nivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

  • Download
  • 7
    Oct.
  • Wed, 15 Jun 16 07:00:00 -0400

    Nivalis Therapeutics to Present at the JMP Securities Life Sciences Conference

  • Download
  • 7
    Oct.
  • Wed, 01 Jun 16 07:00:00 -0400

    Nivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference

  • Download
  • 7
    Oct.
  • Mon, 16 May 16 16:05:00 -0400

    Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Mon, 02 May 16 16:05:00 -0400

    Nivalis Therapeutics Reports First Quarter 2016 Financial Results

  • Download
  • 7
    Oct.
  • Fri, 22 Apr 16 16:05:00 -0400

    Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • Download
  • 7
    Oct.
  • Mon, 18 Apr 16 07:00:00 -0400

    Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery

  • Download
  • 7
    Oct.
  • Tue, 05 Apr 16 08:00:00 -0400

    Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Mon, 07 Mar 16 16:05:00 -0500

    Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Wed, 02 Mar 16 08:00:00 -0500

    Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

  • Download
  • 7
    Oct.
  • Tue, 01 Mar 16 16:05:00 -0500

    Nivalis Therapeutics Announces Appointment of Paul Sekhri to Its Board of Directors

  • Download
  • 7
    Oct.
  • Mon, 29 Feb 16 16:05:00 -0500

    Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2015 Financial Results

  • Download
  • 7
    Oct.
  • Thu, 18 Feb 16 16:05:00 -0500

    Nivalis Therapeutics Announces FDA Fast Track Designation for N91115 in Patients With Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Fri, 15 Jan 16 11:16:00 -0500

    Nivalis Therapeutics Announces FDA Orphan Drug Designation for N91115 in Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Tue, 01 Dec 15 07:00:00 -0500

    Nivalis Therapeutics Announces First Patient Dosed in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Tue, 10 Nov 15 07:00:00 -0500

    Nivalis Therapeutics to Present at the Stifel Healthcare Conference 2015

  • Download
  • 7
    Oct.
  • Mon, 02 Nov 15 16:05:00 -0500

    Nivalis Therapeutics Reports Third Quarter and Nine-Month Financial Results for 2015

  • Download

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.